FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.
biospace · 6d ago

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

PUBLIC COMPANY

save

Convergent Therapeutics Inc

updated 18d ago

Website

community read0 votes

pipeline

marketed

phase 3

catalysts ytd

approvals ytd

recalls ytd

Pipeline(1)

pipeline depth1 products

1Phase 2

Phase 2

rosopatamab tetraxetan

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

Active trials

phase2Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)recruitingn=60

🐶 Hiring Signal

No open roles indexed yet — view Convergent Therapeutics Inc jobs →

News

FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.
biospace · 6d ago

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

Convergent Therapeutics Inc

Pipeline(1)

📅 Upcoming

🕒 Recent(90d)

Active trials

News

comments(0)

Convergent Therapeutics Inc

Pipeline(1)

📅 Upcoming

🕒 Recent(90d)

Active trials

News

comments(0)

Upcoming

Recent(90d)

Upcoming

Recent(90d)